> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Foghorn’s $83.5 Million Revenue Includes $74.1 Million Accounting Catch-Up As It Refocuses Research
- URL: https://www.bullished.co/foghorns-83-5-million-revenue-includes-74-1-million-accounting-catch-up-as-it-refocuses-39760e70/
- Published: 2026-11-09T12:26:04.000Z
- Updated: 2026-11-09T12:26:04.000Z
- Description: The company is prioritizing wholly owned bowel-disease and cancer programs, with cash it expects to last into the second half of 2029.
- Author: Matteo Parrino
- Tags: SEC Filings, FHTX, Industry: Healthcare

Foghorn Therapeutics, which develops experimental cancer and inflammatory-disease medicines, reported $83.5 million in third-quarter collaboration revenue Monday, including a $74.1 million accounting catch-up tied primarily to its decision not to advance FHD-909 and a selective SMARCA2 degrader. The results, announced with an [SEC filing](https://www.sec.gov/Archives/edgar/data/0001822462/000162828026071871/fhtx-20261109.htm?ref=bullished.co), put its wholly owned research portfolio at the center of its update.

## The Adjustment Behind The Profit

Collaboration revenue was $8.2 million in the year-earlier quarter. Foghorn said the accounting adjustment came primarily from revising estimates of future costs associated with the programs it decided against advancing.

The company reported [net income](https://www.sec.gov/Archives/edgar/data/0001822462/000162828026071871/ex991earningspressrelease1.htm?ref=bullished.co) of $58.2 million, versus a $15.8 million loss a year earlier. Diluted earnings were $0.80 a share, compared with a $0.25 loss.

Research and development spending declined to $18.8 million from $20.0 million. Lower costs for Lilly-partnered programs, personnel, facilities and information technology outweighed higher early-development and other outside costs. Administrative spending fell to $5.8 million from $6.7 million, with reductions in personnel, professional and consulting services, facilities and information technology.

Restructuring costs of $2.272 million brought total operating expenses to $26.904 million, compared with $26.654 million a year earlier.

## Bowel Disease And Blood Cancer

“Our focus is on advancing our [wholly owned portfolio](https://www.sec.gov/Archives/edgar/data/0001822462/000162828026071871/ex991earningspressrelease1.htm?ref=bullished.co),” said Adrian Gottschalk, president and chief executive officer of Foghorn Therapeutics. Its work includes oral small molecules, drugs that destroy selected proteins and approaches that bring proteins together to trigger their removal.

The oral inflammatory-bowel-disease candidate reduced disease activity in mouse colitis models, with results comparable to an antibody used as a positive control. Foghorn expects dose-range studies to begin in the fourth quarter of 2026, with potential human studies by the end of 2027.

The blood-cancer program targets EP300 while sparing the closely related protein CBP. Foghorn said their similarity has complicated selective drug development, and blocking both has been associated with toxic effects that restrict dosing.

In preclinical comparisons, the EP300 candidate delivered stronger tumor responses than inobrodib, which inhibits both proteins. Foghorn also reported better results on body-weight loss and platelet counts, plus tumor regression in a multiple myeloma model resistant to pomalidomide. The company targets an application to begin clinical testing in 2027, focusing on multiple myeloma and diffuse large B-cell lymphoma.

## More Targets, Cash Into 2029

Foghorn’s additional research approach seeks to destroy secreted proteins and proteins destined for the cell surface before they arrive there or enter circulation. The company’s goal is to achieve effects comparable to antibodies using small molecules, with potential applications in cancer, inflammatory diseases and other conditions.

Its [investor presentation](https://www.sec.gov/Archives/edgar/data/0001822462/000162828026071871/final%5Fnovxinvestorpresen.htm?ref=bullished.co) also describes FHT-171, a preclinical selective CBP degrader for estrogen-receptor-positive breast cancer. The company reported anti-tumor activity in models resistant to standard treatments and no effect on platelet counts in its animal studies.

Foghorn held $156.2 million in cash, cash equivalents and marketable securities at September 30, 2026\. Management expects those resources to fund operations into the second half of 2029.

The next research milestone is the bowel-disease program’s expected fourth-quarter dose-range studies; potential human testing remains targeted for the end of 2027.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Foghorn Therapeutics Inc. (FHTX)](https://www.sec.gov/Archives/edgar/data/0001822462/000162828026071871/fhtx-20261109.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ex991earningspressrelease1.htm — Foghorn Therapeutics Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001822462/000162828026071871/ex991earningspressrelease1.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit final\_novxinvestorpresen.htm — Foghorn Therapeutics Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001822462/000162828026071871/final%5Fnovxinvestorpresen.htm?ref=bullished.co) — SEC EDGAR